Cargando…

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary

BACKGROUND: The cervical cancer screening program implemented in Hungary to date has not been successful. Along with screening, vaccination is an effective intervention to prevent cervical cancer. The aim of this study was to assess the cost-effectiveness of adding vaccination with the human papillo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vokó, Zoltán, Nagyjánosi, László, Kaló, Zoltán
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528422/ https://www.ncbi.nlm.nih.gov/pubmed/23110361 http://dx.doi.org/10.1186/1471-2458-12-924

Ejemplares similares

Contribution of clinical trials to gross domestic product in Hungary
por: Kaló, Zoltán, et al.
Publicado: (2014)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
por: Germar, Maria Julieta, et al.
Publicado: (2017)

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
por: Kim, Young-Jae, et al.
Publicado: (2010)

Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania()()
por: Brown, Joelle, et al.
Publicado: (2014)

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
por: Kim, Seung Cheol, et al.
Publicado: (2011)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience
por: Angelo, Maria-Genalin, et al.
Publicado: (2014)

Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh
por: Khatun, Sabera, et al.
Publicado: (2012)

Meta‐analysis of the risk of autoimmune thyroiditis, Guillain‐Barré syndrome, and inflammatory bowel disease following vaccination with AS04‐adjuvanted human papillomavirus 16/18 vaccine
por: Rosillon, Dominique, et al.
Publicado: (2020)

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
por: Angelo, Maria-Genalin, et al.
Publicado: (2014)

General practitioners can increase participation in cervical cancer screening – a model program in Hungary
por: Gyulai, Anikó, et al.
Publicado: (2018)

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women: Open follow-up of a randomized clinical trial up to 4 years post-vaccination
por: Konno, Ryo, et al.
Publicado: (2014)

Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study
por: Namujju, Proscovia B, et al.
Publicado: (2014)

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial
por: Zhu, Feng-Cai, et al.
Publicado: (2011)

Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
por: Willame, Corinne, et al.
Publicado: (2016)

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial
por: Huang, Li-Min, et al.
Publicado: (2017)

Incremental cost of premature birth – a public health care payer perspective from Hungary
por: Kovács, Gábor, et al.
Publicado: (2023)

Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2018)

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study
por: Vokó, Zoltán, et al.
Publicado: (2022)

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017)

Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
por: Bonanni, Paolo, et al.
Publicado: (2015)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women
por: Sow, Papa Salif, et al.
Publicado: (2013)

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
por: Lehtinen, Matti, et al.
Publicado: (2016)

Erratum to: Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2020)

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial
por: Garland, Suzanne M., et al.
Publicado: (2016)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
por: Folschweiller, Nicolas, et al.
Publicado: (2019)

Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening
por: Huh, Warner K., et al.
Publicado: (2014)

Pitfalls associated with the therapeutic reference pricing practice of asthma medication
por: Kalo, Zoltan, et al.
Publicado: (2012)

Cost‐effectiveness of possible future smoking cessation strategies in Hungary: results from the EQUIPTMOD
por: Németh, Bertalan, et al.
Publicado: (2018)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
por: Govan, Vandana A
Publicado: (2008)

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial
por: Leung, Ting Fan, et al.
Publicado: (2015)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
por: Nakalembe, Miriam, et al.
Publicado: (2014)

Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years
por: Bi, Dan, et al.
Publicado: (2019)

Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary
por: Bogos, Krisztina, et al.
Publicado: (2019)

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_j57f6t518or30uh1mbaa53ffcq